ERBB2 and triple-negative breast carcinoma: Estrogen receptor (ER) positivity was noted in 62.9%, progesterone receptor (PR) positivity in 57.1%, human epidermal growth factor receptor 2 (HER2/neu) overexpression in 25.7%, and triple-negative breast cancer in 17.1% of cases.